We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

YHLO Helps China’s Top Ranking Hospital PUMCH to Upgrade from Traditional ELISA to CLIA Technology

By LabMedica International staff writers
Posted on 06 Jan 2021
Shenzhen YHLO Biotech Co., Ltd. (Shenzhen, China) has helped China’s top ranking hospital, Peking Union Medical College Hospital (PUMCH; Beijing, China), to successfully upgrade its laboratory from the traditional ELISA (enzyme-linked immunoassay) technology to CLIA (chemiluminescence immunoassay) technology.

PUMCH, founded by the Rockefeller Foundation in 1921, has been designated by China’s Ministry of Health as one of the most authoritative centers for diagnosis and treatment of complex diseases. PUMCH’s department of Rheumatology and Immunology is the earliest dedicated department for rheumatology and immunology in China. The department’s laboratory is capable of diagnosing nearly 100 kinds of auto-antibodies, making it one of the largest auto-antibody diagnosing centers in China. In August 2020, the department upgraded its laboratory from the traditional ELISA technology to CLIA technology with the cooperation of YHLO.

Image: iModules Integration System for Immunoassay (Photo courtesy of Shenzhen YHLO Biotech Co., Ltd.)
Image: iModules Integration System for Immunoassay (Photo courtesy of Shenzhen YHLO Biotech Co., Ltd.)

With the help of YHLO’s iModules Integration System for Immunoassay, PUMCH has become the first among the top Chinese hospitals to establish a fully automated assembly line. YHLO’s iModules series features a modular design that offers flexibility for expansion. With its high throughput, fast speed and multiple parameters, the series helps to process a higher number of samples in the laboratory, improve diagnostic results and shorten turnaround time. The parameters on the iModules platform include dsDNA IgG, SSA IgG, SSB IgG, RNP70 IgG, Sm IgG, Jo-1 IgG, Scl-70 IgG, anti-CCP, MPO IgG, PR3 IgG, Cardiolipin IgG/IgA/IgM/total and β2 Glycoprotein IgG/IgA/IgM/total, etc., providing more accurate and reliable quantitative results.

Related Links:
Shenzhen YHLO Biotech Co., Ltd.
Peking Union Medical College Hospital



New
Gold Member
Latex Test
SLE-Latex Test
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Chlamydia Trachomatis Test
Aptima Chlamydia Trachomatis Assay
New
Clostridium Difficile Toxin A+B Combo Card Test
CerTest Clostridium Difficile Toxin A+B

Latest Industry News

AMP Releases Best Practice Recommendations to Guide Clinical Laboratories Offering HRD Testing
06 Jan 2021  |   Industry

Illumina Acquires SomaLogic to Accelerate Proteomics Business
06 Jan 2021  |   Industry

Qiagen and Gencurix Partner on Development of QIAcuity Digital PCR IVD Assay
06 Jan 2021  |   Industry